CLSN Share Price

Open 0.63 Change Price %
High 0.71 1 Day 0.00 0.00
Low 0.63 1 Week -0.16 -19.05
Close 0.68 1 Month -0.21 -23.60
Volume 99805 1 Year -1.36 -66.67
52 Week High 2.05
52 Week Low 0.62
CLSN Important Levels
Resistance 2 0.75
Resistance 1 0.72
Pivot 0.67
Support 1 0.64
Support 2 0.61
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.67 0.17%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OPXAW 0.01 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Celsion Corporation (NASDAQ: CLSN)

CLSN Technical Analysis 5
As on 2nd Dec 2016 CLSN Share Price closed @ 0.68 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.29 & Strong Sell for SHORT-TERM with Stoploss of 1.03 we also expect STOCK to react on Following IMPORTANT LEVELS.
CLSN Target for December
1st Target up-side 0.91
2nd Target up-side 1.09
3rd Target up-side 1.27
1st Target down-side 0.39
2nd Target down-side 0.21
3rd Target down-side 0.03
CLSN Other Details
Segment EQ
Market Capital 148527728.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.celsion.com
CLSN Address
CLSN
997 Lenox Drive
Suite 100
Lawrenceville, NJ 08648
United States
Phone: 609-896-9100
Fax: 609-896-2200
CLSN Latest News
Interactive Technical Analysis Chart Celsion Corporation ( CLSN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Celsion Corporation
CLSN Business Profile
Celsion Corporation is an oncology drug development company focused on the development of treatments for those suffering with difficult to treat forms of cancer. As of December 31, 2011, the Company's product ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer (the HEAT study), a Phase II clinical trial for colorectal liver metastasis (CRLM) and a Phase II clinical trial for recurrent chest wall breast cancer. ThermoDox is a liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a range of cancers. Localized heat at mild hyperthermia temperatures releases the encapsulated doxorubicin from the liposome enabling high concentrations of doxorubicin to be deposited preferentially in and around the targeted tumor. Liposomes are manufactured submicroscopic vesicles consisting of a discrete aqueous central compartment surrounded by a membrane bilayer consisted of naturally occurring lipids.